Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies
Philip Mendez, Alanis Rosado, Juan Carlos Cardet · 2026
Read Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies by Philip Mendez, Alanis Rosado, Juan Carlos Cardet (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582353.txt.
Description
Philip Mendez, Alanis Rosado, and Juan Carlos Cardet review type two-low asthma, a form with low marks of the usual swollen-airway type. Their review appeared in twenty twenty-six. This form is a large unmet need since steroid drugs often fail and few aimed cures exist. It hits a fair share of adults with asthma and up to three in five kids.
Fresh work ties the form to non-type-two paths, like IL-17 signs and innate immune sparks. Weight gain, old age of the immune set, and ozone in air add to the mix. Long-term germ drugs and one aimed biologic drug cut flare-ups well. New weight-drug paths may add help, but clear marks to match cures are still due.
Catalog record
| CREATOR | Philip Mendez, Alanis Rosado, Juan Carlos Cardet |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |